Astellas taps Poseida for second CAR-T deal focused on solid tumors
Astellas Pharma is signing Poseida Therapeutics to a second deal focused on developing off-the-shelf solid tumor cell therapies after the companies first teamed up in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.